Short-term tibolone does not interfere with endothelial function: a double-blinded, randomized, controlled trial

Area of Science:

• Endocrinology
• Cardiovascular Health
• Women's Health

Background:

• Menopause is associated with increased cardiovascular risk.
• Hormone replacement therapy (HRT) is used to manage menopausal symptoms.
• Endothelial dysfunction is an early marker of atherosclerosis.

Purpose of the Study:

• To assess the impact of short-term tibolone therapy on endothelial function.
• To evaluate changes in flow-mediated dilation (FMD) of the brachial artery.
• To determine if tibolone improves endothelial-dependent vasodilation in postmenopausal women.

Main Methods:

• Randomized, double-blinded, placebo-controlled trial.
• 100 healthy postmenopausal women received tibolone (2.5 mg/day) or placebo for 28 days.
• Brachial artery FMD measured before and after treatment.

Main Results:

• Baseline FMD measurements were similar between tibolone and placebo groups.
• No significant differences in FMD values were observed post-treatment in either group.
• The number of women showing FMD improvement was comparable between groups.

Conclusions:

• Tibolone (2.5 mg/day) for 28 days does not enhance endothelial function in healthy postmenopausal women.
• No significant endothelial-dependent vasodilation was detected via FMD.
• Short-term tibolone therapy does not appear to benefit vascular health in this population.